Sinusitis News and Research

Latest Sinusitis News and Research

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

Patients with CRS can benefit from balloon sinus dilation procedure

Results published in the January/February, 2011 issue of International Forum of Allergy & Rhinology demonstrate that patients with chronic rhinosinusitis who receive treatment with balloon sinus dilation can experience significant improvement in work productivity.

31 Mar 2011

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

ViroPharma Incorporated today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology Annual Meeting, March 18 through 22, in San Francisco, CA.

23 Mar 2011

Survey: AR symptoms continue to impact patients' daily activities

Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.

22 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

A recent trial of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis found the safety profile to be consistent with other RA trials with TNF inhibitors.

8 Mar 2011

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

Depression negatively impacts outcomes of care in patients with CRS: New research

Depression is a common problem in patients with chronic rhinosinusitis and negatively impacts patients' symptom burden, ability to function, and quality of life, according to new research published in the March 2011 issue of Otolaryngology - Head and Neck Surgery.

1 Mar 2011

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical, a Minnesota-based medical technology company, announced today that the U.S. Food and Drug Administration cleared the company's new FinESS Endoscope.

23 Feb 2011

Entellus Medical enters license agreement with Acclarent to resolve patent lawsuit

Entellus Medical today announced that it has entered into a licensing agreement with Acclarent, Inc. in order to resolve their patent lawsuit. The license agreement is royalty bearing to Acclarent.

18 Feb 2011

Experts say signs and treatment of bacterial infection often misunderstood

According to the Canadian Foundation for Infectious Diseases, antibiotics are the second most frequently prescribed class of drugs - second only to pain relievers. Yet most people don't know the difference between a true bacterial infection, like chronic bronchitis that can be treated with antibiotics — and viruses like the common cold, which cannot.

17 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

Researchers from Virginia Mason Medical Center in Seattle, WA, have found that clinical decision support systems can help reduce inappropriate medical imaging, including unnecessary computed tomography (CT) and magnetic resonance imaging (MRI) scans, according to a study in the January issue of the Journal of the American College of Radiology (www.jacr.org).

4 Jan 2011

SinoFresh, Green Valley Drug enter marketing relationship for Homeopathic Antiseptic Nasal Spray

SinoFresh® HealthCare, Inc., is pleased to announce that its marketing division has secured an agency marketing relationship with Green Valley Drug, the largest medical supplier in Southern Nevada with a significant pharmacy and medical customer base in the western U.S.

3 Jan 2011

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.

19 Dec 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.

10 Nov 2010

Sinusitis News and Research

Latest Sinusitis News and Research

Merck enters definitive agreement to acquire Inspire

Patients with CRS can benefit from balloon sinus dilation procedure

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

Survey: AR symptoms continue to impact patients' daily activities

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

FDA approves change to prescribing information for Gilead Sciences' Letairis

Depression negatively impacts outcomes of care in patients with CRS: New research

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical enters license agreement with Acclarent to resolve patent lawsuit

Experts say signs and treatment of bacterial infection often misunderstood

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

SinoFresh, Green Valley Drug enter marketing relationship for Homeopathic Antiseptic Nasal Spray

CF patients with normal to mildly impaired lung function may benefit from new investigational drug

VYTORIN reduces major vascular events in patients with chronic kidney disease

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Sinusitis News and Research

Latest Sinusitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in